CA3192786A1 - Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof - Google Patents

Info

Publication number

CA3192786A1

CA3192786A1 CA3192786A CA3192786A CA3192786A1 CA 3192786 A1 CA3192786 A1 CA 3192786A1 CA 3192786 A CA3192786 A CA 3192786A CA 3192786 A CA3192786 A CA 3192786A CA 3192786 A1 CA3192786 A1 CA 3192786A1

Authority

CA

Canada

Prior art keywords

kda

polysaccharide

immunogenic composition

gbs

serotype

Prior art date

2020-08-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 239000000203 mixture Substances 0.000 title claims abstract description 400
• 230000002163 immunogen Effects 0.000 title claims abstract description 363
• 241000193990 Streptococcus sp. 'group B' Species 0.000 title claims abstract description 356
• 238000000034 method Methods 0.000 title claims abstract description 181
• 229920001282 polysaccharide Polymers 0.000 claims abstract description 754
• 239000005017 polysaccharide Substances 0.000 claims abstract description 754
• 150000004676 glycans Chemical class 0.000 claims abstract description 752
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 174
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 174
• 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 130
• 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 130
• 230000028993 immune response Effects 0.000 claims abstract description 49
• 241000193985 Streptococcus agalactiae Species 0.000 claims abstract description 31
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
• 201000010099 disease Diseases 0.000 claims abstract description 30
• 230000001939 inductive effect Effects 0.000 claims abstract description 18
• 239000002671 adjuvant Substances 0.000 claims description 58
• 150000001720 carbohydrates Chemical group 0.000 claims description 49
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 45
• 238000007254 oxidation reaction Methods 0.000 claims description 42
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 41
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
• 239000000872 buffer Substances 0.000 claims description 33
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 32
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
• -1 fatty acid esters Chemical class 0.000 claims description 25
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 23
• 229920000053 polysorbate 80 Polymers 0.000 claims description 23
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 22
• 229940068968 polysorbate 80 Drugs 0.000 claims description 22
• 239000011780 sodium chloride Substances 0.000 claims description 22
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
• 230000003647 oxidation Effects 0.000 claims description 21
• 229930006000 Sucrose Natural products 0.000 claims description 19
• 239000005720 sucrose Substances 0.000 claims description 19
• 238000002360 preparation method Methods 0.000 claims description 17
• 239000004471 Glycine Substances 0.000 claims description 16
• 239000004094 surface-active agent Substances 0.000 claims description 16
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
• 229930195725 Mannitol Natural products 0.000 claims description 15
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 15
• 239000000594 mannitol Substances 0.000 claims description 15
• 235000010355 mannitol Nutrition 0.000 claims description 15
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 14
• 229960000814 tetanus toxoid Drugs 0.000 claims description 14
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 13
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 12
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 11
• SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 11
• QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 11
• 229920002307 Dextran Polymers 0.000 claims description 11
• MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 11
• UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 11
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 11
• MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 11
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 11
• 230000036039 immunity Effects 0.000 claims description 11
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 11
• 239000000832 lactitol Substances 0.000 claims description 11
• VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 11
• 235000010448 lactitol Nutrition 0.000 claims description 11
• 229960003451 lactitol Drugs 0.000 claims description 11
• QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 11
• MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 11
• UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 11
• 229920001214 Polysorbate 60 Polymers 0.000 claims description 9
• 239000007987 MES buffer Substances 0.000 claims description 8
• 239000003599 detergent Substances 0.000 claims description 8
• 239000008103 glucose Substances 0.000 claims description 8
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
• 239000004475 Arginine Substances 0.000 claims description 7
• 108010010803 Gelatin Proteins 0.000 claims description 7
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
• 239000004472 Lysine Substances 0.000 claims description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 7
• 235000007164 Oryza sativa Nutrition 0.000 claims description 7
• 229920002472 Starch Polymers 0.000 claims description 7
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
• 229960003983 diphtheria toxoid Drugs 0.000 claims description 7
• 239000003814 drug Substances 0.000 claims description 7
• 235000013312 flour Nutrition 0.000 claims description 7
• 239000008273 gelatin Substances 0.000 claims description 7
• 229920000159 gelatin Polymers 0.000 claims description 7
• 235000019322 gelatine Nutrition 0.000 claims description 7
• 235000011852 gelatine desserts Nutrition 0.000 claims description 7
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 7
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 7
• 239000008101 lactose Substances 0.000 claims description 7
• 235000009566 rice Nutrition 0.000 claims description 7
• 239000000741 silica gel Substances 0.000 claims description 7
• 229910002027 silica gel Inorganic materials 0.000 claims description 7
• 235000020183 skimmed milk Nutrition 0.000 claims description 7
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 7
• 239000008107 starch Substances 0.000 claims description 7
• 235000019698 starch Nutrition 0.000 claims description 7
• 239000000454 talc Substances 0.000 claims description 7
• 229910052623 talc Inorganic materials 0.000 claims description 7
• 229920001219 Polysorbate 40 Polymers 0.000 claims description 6
• 150000001768 cations Chemical class 0.000 claims description 6
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 6
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 6
• 229940101027 polysorbate 40 Drugs 0.000 claims description 6
• 150000003254 radicals Chemical class 0.000 claims description 6
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 6
• IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical group OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
• 239000007995 HEPES buffer Substances 0.000 claims description 5
• 239000007990 PIPES buffer Substances 0.000 claims description 5
• 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
• 239000007983 Tris buffer Substances 0.000 claims description 5
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
• 150000003839 salts Chemical class 0.000 claims description 5
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 4
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
• 229910019142 PO4 Inorganic materials 0.000 claims description 4
• 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
• 150000005215 alkyl ethers Chemical class 0.000 claims description 4
• 239000002577 cryoprotective agent Substances 0.000 claims description 4
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
• 239000000194 fatty acid Substances 0.000 claims description 4
• 229930195729 fatty acid Natural products 0.000 claims description 4
• 239000003112 inhibitor Substances 0.000 claims description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
• 239000010452 phosphate Substances 0.000 claims description 4
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 4
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 4
• 229940068977 polysorbate 20 Drugs 0.000 claims description 4
• 229940113124 polysorbate 60 Drugs 0.000 claims description 4
• 239000003381 stabilizer Substances 0.000 claims description 4
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 3
• 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
• 240000007594 Oryza sativa Species 0.000 claims 1
• 208000015181 infectious disease Diseases 0.000 abstract description 20
• 238000009169 immunotherapy Methods 0.000 abstract description 3
• 239000000562 conjugate Substances 0.000 description 341
• 230000009450 sialylation Effects 0.000 description 88
• 230000021615 conjugation Effects 0.000 description 84
• 102000004169 proteins and genes Human genes 0.000 description 70
• 108090000623 proteins and genes Proteins 0.000 description 70
• 239000000427 antigen Substances 0.000 description 68
• 108091007433 antigens Proteins 0.000 description 68
• 102000036639 antigens Human genes 0.000 description 68
• 210000004027 cell Anatomy 0.000 description 60
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 43
• 241000894006 Bacteria Species 0.000 description 38
• 238000006243 chemical reaction Methods 0.000 description 28
• 241001465754 Metazoa Species 0.000 description 26
• 238000003556 assay Methods 0.000 description 26
• 238000004519 manufacturing process Methods 0.000 description 26
• 229960005486 vaccine Drugs 0.000 description 25
• 108010059574 C5a peptidase Proteins 0.000 description 24
• 239000007800 oxidant agent Substances 0.000 description 23
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 22
• 230000001580 bacterial effect Effects 0.000 description 22
• 239000002775 capsule Substances 0.000 description 22
• 108090000765 processed proteins & peptides Proteins 0.000 description 19
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
• 238000007792 addition Methods 0.000 description 18
• 230000005847 immunogenicity Effects 0.000 description 18
• 239000003638 chemical reducing agent Substances 0.000 description 17
• 229920001542 oligosaccharide Polymers 0.000 description 16
• 150000002482 oligosaccharides Chemical class 0.000 description 16
• 210000001744 T-lymphocyte Anatomy 0.000 description 15
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 15
• 239000003153 chemical reaction reagent Substances 0.000 description 15
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical group OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 15
• 230000035935 pregnancy Effects 0.000 description 15
• 238000010791 quenching Methods 0.000 description 15
• 230000000171 quenching effect Effects 0.000 description 15
• 241000283973 Oryctolagus cuniculus Species 0.000 description 14
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 14
• 229910052782 aluminium Inorganic materials 0.000 description 14
• 210000002966 serum Anatomy 0.000 description 14
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 14
• 150000001299 aldehydes Chemical class 0.000 description 13
• 230000027455 binding Effects 0.000 description 13
• 239000003085 diluting agent Substances 0.000 description 13
• 239000000463 material Substances 0.000 description 13
• 230000008569 process Effects 0.000 description 13
• 102000004196 processed proteins & peptides Human genes 0.000 description 13
• 239000008215 water for injection Substances 0.000 description 13
• 239000003795 chemical substances by application Substances 0.000 description 11
• 238000011026 diafiltration Methods 0.000 description 11
• 230000003053 immunization Effects 0.000 description 11
• 238000000338 in vitro Methods 0.000 description 11
• 230000002147 killing effect Effects 0.000 description 11
• 238000006722 reduction reaction Methods 0.000 description 11
• 238000006268 reductive amination reaction Methods 0.000 description 11
• 239000012279 sodium borohydride Substances 0.000 description 11
• 229910000033 sodium borohydride Inorganic materials 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• 241000282414 Homo sapiens Species 0.000 description 10
• 238000002649 immunization Methods 0.000 description 10
• 239000002609 medium Substances 0.000 description 10
• GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 10
• 150000002772 monosaccharides Chemical group 0.000 description 10
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 10
• 108060003951 Immunoglobulin Proteins 0.000 description 9
• 239000000969 carrier Substances 0.000 description 9
• 230000008878 coupling Effects 0.000 description 9
• 238000010168 coupling process Methods 0.000 description 9
• 238000005859 coupling reaction Methods 0.000 description 9
• 230000000694 effects Effects 0.000 description 9
• 238000001914 filtration Methods 0.000 description 9
• 210000004408 hybridoma Anatomy 0.000 description 9
• 102000018358 immunoglobulin Human genes 0.000 description 9
• 239000004615 ingredient Substances 0.000 description 9
• 230000001662 opsonic effect Effects 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• 208000035473 Communicable disease Diseases 0.000 description 8
• 241000194017 Streptococcus Species 0.000 description 8
• 230000005875 antibody response Effects 0.000 description 8
• 235000014633 carbohydrates Nutrition 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 238000013329 compounding Methods 0.000 description 8
• FJEKYHHLGZLYAT-FKUIBCNASA-N galp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C1=CNC=N1 FJEKYHHLGZLYAT-FKUIBCNASA-N 0.000 description 8
• 239000001963 growth medium Substances 0.000 description 8
• 239000003880 polar aprotic solvent Substances 0.000 description 8
• 229920001184 polypeptide Polymers 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
• DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 7
• 150000003923 2,5-pyrrolediones Chemical class 0.000 description 7
• 241000124008 Mammalia Species 0.000 description 7
• 229910000085 borane Inorganic materials 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 238000011282 treatment Methods 0.000 description 7
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 206010061598 Immunodeficiency Diseases 0.000 description 6
• 102100020870 La-related protein 6 Human genes 0.000 description 6
• 108050008265 La-related protein 6 Proteins 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• 206010028980 Neoplasm Diseases 0.000 description 6
• 241000209094 Oryza Species 0.000 description 6
• 230000000844 anti-bacterial effect Effects 0.000 description 6
• 230000000890 antigenic effect Effects 0.000 description 6
• OJKZEZMAPKWHTG-UHFFFAOYSA-N bis(2h-triazol-4-yl)methanone Chemical compound C=1NN=NC=1C(=O)C1=CNN=N1 OJKZEZMAPKWHTG-UHFFFAOYSA-N 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 238000005119 centrifugation Methods 0.000 description 6
• 230000000295 complement effect Effects 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 206010012601 diabetes mellitus Diseases 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• 239000000839 emulsion Substances 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 230000000625 opsonophagocytic effect Effects 0.000 description 6
• 230000001681 protective effect Effects 0.000 description 6
• 125000000185 sucrose group Chemical group 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 5
• PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 5
• 208000024172 Cardiovascular disease Diseases 0.000 description 5
• 108010060123 Conjugate Vaccines Proteins 0.000 description 5
• 208000031886 HIV Infections Diseases 0.000 description 5
• 208000037357 HIV infectious disease Diseases 0.000 description 5
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
• 208000008589 Obesity Diseases 0.000 description 5
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 5
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
• 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 5
• PTTGRYBBCYZPSL-UHFFFAOYSA-H [Al+3].[Al+3].OOP([O-])([O-])=O.OOP([O-])([O-])=O.OOP([O-])([O-])=O Chemical compound [Al+3].[Al+3].OOP([O-])([O-])=O.OOP([O-])([O-])=O.OOP([O-])([O-])=O PTTGRYBBCYZPSL-UHFFFAOYSA-H 0.000 description 5
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• 210000002421 cell wall Anatomy 0.000 description 5
• 229940031670 conjugate vaccine Drugs 0.000 description 5
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 238000000265 homogenisation Methods 0.000 description 5
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
• 239000002955 immunomodulating agent Substances 0.000 description 5
• 229940121354 immunomodulator Drugs 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 210000000265 leukocyte Anatomy 0.000 description 5
• 230000021633 leukocyte mediated immunity Effects 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 208000019423 liver disease Diseases 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 235000020824 obesity Nutrition 0.000 description 5
• 244000052769 pathogen Species 0.000 description 5
• 230000001717 pathogenic effect Effects 0.000 description 5
• 238000001556 precipitation Methods 0.000 description 5
• 239000003755 preservative agent Substances 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 239000004576 sand Substances 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 229940031439 squalene Drugs 0.000 description 5
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 208000031942 Late Onset disease Diseases 0.000 description 4
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
• 201000009906 Meningitis Diseases 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 208000020241 Neonatal disease Diseases 0.000 description 4
• 208000037129 Newborn Diseases Infant Diseases 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 4
• 229940098773 bovine serum albumin Drugs 0.000 description 4
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 230000001268 conjugating effect Effects 0.000 description 4
• 230000009260 cross reactivity Effects 0.000 description 4
• 238000009295 crossflow filtration Methods 0.000 description 4
• 239000008121 dextrose Substances 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 239000012634 fragment Substances 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• 210000001539 phagocyte Anatomy 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 229910000160 potassium phosphate Inorganic materials 0.000 description 4
• 235000011009 potassium phosphates Nutrition 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 238000000108 ultra-filtration Methods 0.000 description 4
• SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 239000007848 Bronsted acid Substances 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 241001478240 Coccus Species 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 3
• FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 3
• 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 239000002841 Lewis acid Substances 0.000 description 3
• 239000012448 Lithium borohydride Substances 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• 108010081690 Pertussis Toxin Proteins 0.000 description 3
• 206010057249 Phagocytosis Diseases 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 206010061372 Streptococcal infection Diseases 0.000 description 3
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 3
• 238000006640 acetylation reaction Methods 0.000 description 3
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
• 229940024545 aluminum hydroxide Drugs 0.000 description 3
• RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000012736 aqueous medium Substances 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• QHXLIQMGIGEHJP-UHFFFAOYSA-N boron;2-methylpyridine Chemical compound [B].CC1=CC=CC=N1 QHXLIQMGIGEHJP-UHFFFAOYSA-N 0.000 description 3
• VPEPQDBAIMZCGV-UHFFFAOYSA-N boron;5-ethyl-2-methylpyridine Chemical compound [B].CCC1=CC=C(C)N=C1 VPEPQDBAIMZCGV-UHFFFAOYSA-N 0.000 description 3
• RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 3
• NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 239000012707 chemical precursor Substances 0.000 description 3
• 238000000502 dialysis Methods 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000002443 helper t lymphocyte Anatomy 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 150000007517 lewis acids Chemical class 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• 230000008774 maternal effect Effects 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 238000000569 multi-angle light scattering Methods 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 230000014207 opsonization Effects 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• KHIWWQKSHDUIBK-UHFFFAOYSA-M periodate Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 description 3
• 230000008782 phagocytosis Effects 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 229920001983 poloxamer Polymers 0.000 description 3
• 150000004804 polysaccharides Polymers 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 230000035484 reaction time Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 229930182490 saponin Natural products 0.000 description 3
• 150000007949 saponins Chemical class 0.000 description 3
• 235000017709 saponins Nutrition 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 239000001488 sodium phosphate Substances 0.000 description 3
• 229910000162 sodium phosphate Inorganic materials 0.000 description 3
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
• 241000251468 Actinopterygii Species 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 208000031729 Bacteremia Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 241000193163 Clostridioides difficile Species 0.000 description 2
• 102100031506 Complement C5 Human genes 0.000 description 2
• 241000759568 Corixa Species 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 108010053187 Diphtheria Toxin Proteins 0.000 description 2
• 102000016607 Diphtheria Toxin Human genes 0.000 description 2
• 108010024212 E-Selectin Proteins 0.000 description 2
• 238000012286 ELISA Assay Methods 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 241000606790 Haemophilus Species 0.000 description 2
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 241000270322 Lepidosauria Species 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 108010058846 Ovalbumin Proteins 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 201000005702 Pertussis Diseases 0.000 description 2
• 208000035109 Pneumococcal Infections Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 241000191967 Staphylococcus aureus Species 0.000 description 2
• 241000193998 Streptococcus pneumoniae Species 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 125000003172 aldehyde group Chemical group 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 239000003125 aqueous solvent Substances 0.000 description 2
• WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 2
• 229950010555 avridine Drugs 0.000 description 2
• 244000052616 bacterial pathogen Species 0.000 description 2
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
• 229960001950 benzethonium chloride Drugs 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 150000001718 carbodiimides Chemical class 0.000 description 2
• 230000007969 cellular immunity Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 238000004737 colorimetric analysis Methods 0.000 description 2
• 238000007398 colorimetric assay Methods 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000011969 continuous reassessment method Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 101150044687 crm gene Proteins 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 239000004643 cyanate ester Substances 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000011118 depth filtration Methods 0.000 description 2
• 206010013023 diphtheria Diseases 0.000 description 2
• 150000002016 disaccharides Chemical class 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 238000005227 gel permeation chromatography Methods 0.000 description 2
• 210000000224 granular leucocyte Anatomy 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• 150000002402 hexoses Chemical class 0.000 description 2
• 230000028996 humoral immune response Effects 0.000 description 2
• 230000009851 immunogenic response Effects 0.000 description 2
• 230000002584 immunomodulator Effects 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 244000144972 livestock Species 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 2
• 229960005225 mifamurtide Drugs 0.000 description 2
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
• GXELTROTKVKZBQ-UHFFFAOYSA-N n,n-dibenzylhydroxylamine Chemical compound C=1C=CC=CC=1CN(O)CC1=CC=CC=C1 GXELTROTKVKZBQ-UHFFFAOYSA-N 0.000 description 2
• 239000002736 nonionic surfactant Substances 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 229940092253 ovalbumin Drugs 0.000 description 2
• 230000000242 pagocytic effect Effects 0.000 description 2
• 239000000863 peptide conjugate Substances 0.000 description 2
• 229960005323 phenoxyethanol Drugs 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 108010040473 pneumococcal surface protein A Proteins 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000008057 potassium phosphate buffer Substances 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000001542 size-exclusion chromatography Methods 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 238000012384 transportation and delivery Methods 0.000 description 2
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
• 229940031418 trivalent vaccine Drugs 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 238000002255 vaccination Methods 0.000 description 2
• 238000009736 wetting Methods 0.000 description 2
• PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
• BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
• MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
• YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
• CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
• AWAFMFHOLVZLFG-UHFFFAOYSA-N 1-iodoaziridine-2,3-dione Chemical compound IN1C(=O)C1=O AWAFMFHOLVZLFG-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
• VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
• NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
• AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
• QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
• DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
• NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
• XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 description 1
• OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
• QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
• 239000007988 ADA buffer Substances 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 241000272517 Anseriformes Species 0.000 description 1
• 241000269350 Anura Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
• 241000157302 Bison bison athabascae Species 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 241000588807 Bordetella Species 0.000 description 1
• 241001416153 Bos grunniens Species 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 108010084313 CD58 Antigens Proteins 0.000 description 1
• 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282994 Cervidae Species 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 241000251730 Chondrichthyes Species 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 241000193468 Clostridium perfringens Species 0.000 description 1
• 108010028773 Complement C5 Proteins 0.000 description 1
• 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• 229940032046 DTaP vaccine Drugs 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 101710088341 Dermatopontin Proteins 0.000 description 1
• 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 102000015689 E-Selectin Human genes 0.000 description 1
• 102100023471 E-selectin Human genes 0.000 description 1
• 101710146739 Enterotoxin Proteins 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241001331845 Equus asinus x caballus Species 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 241000699694 Gerbillinae Species 0.000 description 1
• UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
• OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
• GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
• 238000010268 HPLC based assay Methods 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 108010006464 Hemolysin Proteins Proteins 0.000 description 1
• 229910052689 Holmium Inorganic materials 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 101100100117 Homo sapiens TNFRSF10B gene Proteins 0.000 description 1
• 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 1
• 102100025323 Integrin alpha-1 Human genes 0.000 description 1
• 102100022339 Integrin alpha-L Human genes 0.000 description 1
• 108010041341 Integrin alpha1 Proteins 0.000 description 1
• 108010055795 Integrin alpha1beta1 Proteins 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
• 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
• 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 108010092694 L-Selectin Proteins 0.000 description 1
• 102100033467 L-selectin Human genes 0.000 description 1
• 241000282838 Lama Species 0.000 description 1
• 208000035752 Live birth Diseases 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 239000007993 MOPS buffer Substances 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 108010060408 Member 25 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000282339 Mustela Species 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 241000588650 Neisseria meningitidis Species 0.000 description 1
• 208000006816 Neonatal Sepsis Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 108700022034 Opsonin Proteins Proteins 0.000 description 1
• 101710116435 Outer membrane protein Proteins 0.000 description 1
• 108010035766 P-Selectin Proteins 0.000 description 1
• 102100023472 P-selectin Human genes 0.000 description 1
• 101150044441 PECAM1 gene Proteins 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 108010013639 Peptidoglycan Proteins 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 1
• 101710183389 Pneumolysin Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001231 Polysaccharide peptide Polymers 0.000 description 1
• 102000017033 Porins Human genes 0.000 description 1
• 108010013381 Porins Proteins 0.000 description 1
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
• 108010059712 Pronase Proteins 0.000 description 1
• 101710188053 Protein D Proteins 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 1
• 102100028688 Putative glycosylation-dependent cell adhesion molecule 1 Human genes 0.000 description 1
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 101150080148 RR10 gene Proteins 0.000 description 1
• 241000283011 Rangifer Species 0.000 description 1
• 241000981697 Rattus andamanensis Species 0.000 description 1
• 101100194625 Rattus norvegicus Rgs19 gene Proteins 0.000 description 1
• 208000035415 Reinfection Diseases 0.000 description 1
• 101710132893 Resolvase Proteins 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 108010073443 Ribi adjuvant Proteins 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 108700012261 Rotavirus VP7 Proteins 0.000 description 1
• VNPWVMVYUSNFAW-WFMPWKQPSA-N S-inosyl-L-homocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H]([NH3+])C([O-])=O)O[C@H]1N1C2=NC=NC(O)=C2N=C1 VNPWVMVYUSNFAW-WFMPWKQPSA-N 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 241000270295 Serpentes Species 0.000 description 1
• 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 108010008038 Synthetic Vaccines Proteins 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• QYTDEUPAUMOIOP-UHFFFAOYSA-N TEMPO Chemical group CC1(C)CCCC(C)(C)N1[O] QYTDEUPAUMOIOP-UHFFFAOYSA-N 0.000 description 1
• 241000270666 Testudines Species 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 101710182223 Toxin B Proteins 0.000 description 1
• 101710182532 Toxin a Proteins 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 1
• 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 208000037386 Typhoid Diseases 0.000 description 1
• 101710117021 Tyrosine-protein phosphatase YopH Proteins 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 241001416177 Vicugna pacos Species 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
• SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 210000004381 amniotic fluid Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000007998 bicine buffer Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000006041 cell recruitment Effects 0.000 description 1
• 206010008129 cerebral palsy Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 238000002144 chemical decomposition reaction Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 108010031071 cholera toxoid Proteins 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000001332 colony forming effect Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229930003836 cresol Natural products 0.000 description 1
• 229940013361 cresol Drugs 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
• 229940099500 cystamine Drugs 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 238000011266 cytolytic assay Methods 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• FVCOIAYSJZGECG-UHFFFAOYSA-N diethylhydroxylamine Chemical compound CCN(O)CC FVCOIAYSJZGECG-UHFFFAOYSA-N 0.000 description 1
• 150000002009 diols Chemical group 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000000147 enterotoxin Substances 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• MXLOKFOWFPJWCW-UHFFFAOYSA-N ethylzingerone Chemical compound CCOC1=CC(CCC(C)=O)=CC=C1O MXLOKFOWFPJWCW-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000002095 exotoxin Substances 0.000 description 1
• 231100000776 exotoxin Toxicity 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 238000011331 genomic analysis Methods 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 229920000550 glycopolymer Polymers 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229940025294 hemin Drugs 0.000 description 1
• BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
• 239000003228 hemolysin Substances 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
• SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000007236 host immunity Effects 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 150000002443 hydroxylamines Chemical class 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
• 229920006008 lipopolysaccharide Polymers 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 208000018773 low birth weight Diseases 0.000 description 1
• 231100000533 low birth weight Toxicity 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 229940031346 monovalent vaccine Drugs 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
• 108010009719 mutanolysin Proteins 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• DWFKOMDBEKIATP-UHFFFAOYSA-N n'-[2-[2-(dimethylamino)ethyl-methylamino]ethyl]-n,n,n'-trimethylethane-1,2-diamine Chemical compound CN(C)CCN(C)CCN(C)CCN(C)C DWFKOMDBEKIATP-UHFFFAOYSA-N 0.000 description 1
• COFOBGYBKLTPER-UHFFFAOYSA-N n-methyl-n'-[3-(methylamino)propyl]propane-1,3-diamine Chemical compound CNCCCNCCCNC COFOBGYBKLTPER-UHFFFAOYSA-N 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 101150031431 opa gene Proteins 0.000 description 1
• 238000010979 pH adjustment Methods 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 108010022457 polysaccharide peptide Proteins 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 230000002516 postimmunization Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 150000003138 primary alcohols Chemical class 0.000 description 1
• 229940021993 prophylactic vaccine Drugs 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 108020003519 protein disulfide isomerase Proteins 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000005086 pumping Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000000601 reactogenic effect Effects 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 230000003134 recirculating effect Effects 0.000 description 1
• 210000005000 reproductive tract Anatomy 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 239000012465 retentate Substances 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000001881 scanning electron acoustic microscopy Methods 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 208000000995 spontaneous abortion Diseases 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 208000002254 stillbirth Diseases 0.000 description 1
• 231100000537 stillbirth Toxicity 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 108010012704 sulfated glycoprotein p50 Proteins 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000013076 target substance Substances 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
• 229960004089 tigecycline Drugs 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 229960001124 trientine Drugs 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 230000006444 vascular growth Effects 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000001018 virulence Effects 0.000 description 1
• 239000000304 virulence factor Substances 0.000 description 1
• 230000007923 virulence factor Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 239000012138 yeast extract Substances 0.000 description 1